Skip to main content
SpringerLink
Log in

The Cell Cycle and the Molecular Biology of Cancer

  • Chapter
Molecular Pathology of Gynecologic Cancer

Part of the book series: Current Clinical Oncology ((CCO))

  • 989 Accesses

Abstract

Human malignant tumors are characterized by abnormal proliferation resulting from alterations in cell-cycle regulatory mechanisms. The regulatory pathways controlling cell-cycle phases include several oncogenes and tumor suppressor genes, which display a range of abnormalities with potential usefulness as markers of evolution or treatment response in cancer. This chapter summarizes the current knowledge about these aberrations in malignant transformation.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 89.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Stiegler P, Kasten M, Giordano A. The RB family of cell cycle regulatory factors. J Cell Biochem Suppl 1998; 30-31: 30–36.

    Article  PubMed  CAS  Google Scholar 

  2. Paggi MG, Giordano A. Who is the boss in the retinoblastoma family? The point of view of Rb2/pl30, the little brother. Cancer Res 2001; 61(12): 4651–4654.

    PubMed  CAS  Google Scholar 

  3. Carnero A, Hannon GJ. The INK4 family of CDK inhibitors. Curr Top Microbiol Immunol 1998; 227: 43–55.

    PubMed  CAS  Google Scholar 

  4. Hengst L, Reed SI. Inhibitors of the Cip/Kip family. Curr Top Microbiol Immunol 1998; 227: 25–41.

    PubMed  CAS  Google Scholar 

  5. Sherr CJ, Roberts JM. CDK inhibitors: positive and negative regulators of Gl-phase progression. Genes Dev 1999; 13(12): 1501–1512.

    PubMed  CAS  Google Scholar 

  6. Lundberg AS, Weinberg RA. Control of the cell cycle and apoptosis. Eur J Cancer 1999; 35(4): 531–539.

    Article  PubMed  CAS  Google Scholar 

  7. Dulic V, Lees E, Reed SI. Association of human cyclin E with a periodic Gl-S phase protein kinase. Science 1992; 257(5078): 1958–1961.

    Article  PubMed  CAS  Google Scholar 

  8. Koff A, Giordano A, Desai D, et al. Formation and activation of a cyclin E-cdk2 complex during the Gl phase of the human cell cycle. Science 1992; 257(5077): 1689–1694.

    Article  PubMed  CAS  Google Scholar 

  9. Ekholm SV, Zickert P, Reed SI, et al. Accumulation of cyclin E is not a prerequisite for passage through the restriction point Mol Cell Biol 2001; 21(9): 3256–3265.

    Article  PubMed  CAS  Google Scholar 

  10. Sherr CJ, Roberts JM. Inhibitors of mammalian Gl cyclin-dependent kinases. Genes Dev 1995; 9(10): 1149–1163.

    Article  PubMed  CAS  Google Scholar 

  11. Wolowiec D, Mekki Y, Ffrench P, et al. Differential expression of cell proliferation regulatory proteins in B-and T-lineage acute lymphoblastic leukaemias. Br J Haematol 1996; 95(3): 518–523.

    Article  PubMed  CAS  Google Scholar 

  12. Yasui W, Akama Y, Kuniyasu H, et al. Expression of cyclin E in human gastric adenomas and adenocarcinomas: correlation with proliferative activity and p53 status. J Exp Ther Oncol 1996; 1(2): 88–94.

    PubMed  CAS  Google Scholar 

  13. Iida H, Towatari M, Tanimoto M, et al. Overexpression of cyclin E in acute myelogenous leukemia. Blood 1997; 90(9): 3707–3713.

    PubMed  CAS  Google Scholar 

  14. Molendini L, Benassi MS, Magagnoli G, et al. Prognostic significance of cyclin expression in human osteosarcoma. Int J Oncol 1998; 12(5): 1007–1011.

    PubMed  CAS  Google Scholar 

  15. Dong Y, Sui L, Tai Y, et al. Prognostic significance of cyclin E overexpression in laryngeal squamous cell carcinomas. Clin Cancer Res 2000; 6(11): 4253–4258.

    PubMed  CAS  Google Scholar 

  16. Fukuse T, Hirata T, Naiki H, et al. Prognostic significance of cyclin E overexpression in resected non-small cell lung cancer. Cancer Res 2000; 60(2): 242–244.

    PubMed  CAS  Google Scholar 

  17. Erlanson M, Landberg G. Prognostic implications of p27 and cyclin E protein contents in malignant lymphomas. Leuk Lymphoma 2001; 40(5–6): 461–470.

    PubMed  CAS  Google Scholar 

  18. Muller-Tidow C, Metzger R, Kugler K, et al. Cyclin E is the only cyclin-dependent kinase 2-associated cyclin that predicts metastasis and survival in early stage non-small cell lung cancer. Cancer Res 2001; 61(2): 647–653.

    PubMed  CAS  Google Scholar 

  19. Schraml P, Bucher C, Bissig H, et al. Cyclin E overexpression and amplification in human tumours. J Pathol 2003; 200(3): 375–382.

    Article  PubMed  CAS  Google Scholar 

  20. Tissier F, Louvel A, Grabar S, et al. Cyclin E correlates with malignancy and adverse prognosis in adrenocortical tumors. Eur J Endocrinol 2004; 150(6): 809–817.

    Article  PubMed  CAS  Google Scholar 

  21. Ortega S, Malumbres M, Barbacid M. Cyclin D-dependent kinases, INK4 inhibitors and cancer. Biochim Biophys Acta 2002; 1602(1): 73–87.

    PubMed  CAS  Google Scholar 

  22. Lammie GA, Peters G. Chromosome 11ql3 abnormalities in human cancer. Cancer Cells 1991; 3(11): 413–420.

    PubMed  CAS  Google Scholar 

  23. Reissmann PT, Koga H, Figlin RA, Holmes EC, Slamon DJ. Amplification and overexpression of the cyclin Dl and epidermal growth factor receptor genes in non-small-cell lung cancer. Lung Cancer Study Group. J Cancer Res Clin Oncol 1999; 125(2): 61–70.

    Article  PubMed  CAS  Google Scholar 

  24. Rodrigo JP, Garcia LA, Ramos S, Lazo PS, Suarez C. EMS1 gene amplification correlates with poor prognosis in squamous cell carcinomas of the head and neck Clin Cancer Res 2000; 6(8): 3177–3182.

    PubMed  CAS  Google Scholar 

  25. Cheung TH, Yu MM, Lo KW, Yim SF, Chung TK, Wong YF. Alteration of cyclin Dl and CDK4 gene in carcinoma of uterine cervix. Cancer Lett 2001; 166(2): 199–206.

    Article  PubMed  CAS  Google Scholar 

  26. Fujii M, Ishiguro R, Yamashita T, Tashiro M. Cyclin D1 amplification correlates with early recurrence of squamous cell carcinoma of the tongue. Cancer Lett 2001; 172(2): 187–192.

    Article  PubMed  CAS  Google Scholar 

  27. Vielba R, Bilbao J, Ispizua A, et al. p53 and cyclin Dl as prognostic factors in squamous cell carcinoma of the larynx. Laryngoscope 2003; 113(1): 167–172.

    Article  PubMed  CAS  Google Scholar 

  28. Lammie GA, Fantl V, Smith R, et al. Dl 1S287, a putative oncogene on chromosome 11ql3, is amplified and expressed in squamous cell and mammary carcinomas and linked to BCL-1. Oncogene 1991; 6(3): 439–444.

    PubMed  CAS  Google Scholar 

  29. Buckley MF, Sweeny KJ, Hamilton JA, et al. Expression and amplification of cyclin genes in human breast cancer. Oncogene 1993; 8(8): 2127–2133.

    PubMed  CAS  Google Scholar 

  30. Dickson C, Fantl V, Gillett C, et al. Amplification of chromosome band 11ql3 and a role for cyclin Dl in human breast cancer. Cancer Lett 1995; 90(1): 43–50.

    Article  PubMed  CAS  Google Scholar 

  31. Bartkova J, Lukas J, Muller H, Lutzhoft D, Strauss M, Bartek J. Cyclin Dl protein expression and function in human breast cancer. Int J Cancer 1994; 57(3): 353–361.

    Article  PubMed  CAS  Google Scholar 

  32. Bartkova J, Lukas J, Strauss M, Bartek J. Cyclin Dl oncoprotein aberrantly accumulates in malignancies of diverse histogenesis. Oncogene 1995; 10(4): 775–778.

    PubMed  CAS  Google Scholar 

  33. Gillett C, Fantl V, Smith R, et al. Amplification and overexpression of cyclin Dl in breast cancer detected by immunohistochemical staining. Cancer Res 1994; 54(7): 1812–1827.

    PubMed  CAS  Google Scholar 

  34. McIntosh GG, Anderson JJ, Milton I, et al. Determination of the prognostic value of cyclin Dl over-expression in breast cancer. Oncogene 1995; 11(5): 885–891.

    PubMed  CAS  Google Scholar 

  35. Gillett C, Smith P, Gregory W, et al. Cyclin Dl and prognosis in human breast cancer. Int J Cancer 1996; 69(2): 92–99.

    Article  PubMed  CAS  Google Scholar 

  36. Weinstat-Saslow D, Merino MJ, Manrow RE, et al. Overexpression of cyclin D mRNA distinguishes invasive and in situ breast carcinomas from non-malignant lesions. Nat Med 1995; 1(12): 1257–1260.

    Article  PubMed  CAS  Google Scholar 

  37. Delmer A, Ajchenbaum-Cvmbalista F, Tang R, et al. Over-expression of cyclin Dl in chronic B-cell malignancies with abnormality of chromosome 11ql3. Br J Haematol 1995; 89(4): 798–804.

    Article  PubMed  CAS  Google Scholar 

  38. Motokura T, Arnold A. Cyclin D and oncogenesis. Curr Opin Genet Dev 1993; 3(1): 5–10.

    Article  PubMed  CAS  Google Scholar 

  39. Buschges R, Weber RG, Actor B, Lichter P, Collins VP, Reifenberger G. Amplification and expression of cyclin D genes (CCND1, CCND2 and CCND3) in human malignant gliomas. Brain Pathol 1999; 9(3): 435–442; discussion 432-433.

    Article  PubMed  CAS  Google Scholar 

  40. Ito Y, Takeda T, Wakasa K, Tsujimoto M, Matsuura N. Expression and possible role of cyclin D3 in human pancreatic adenocarcinoma. Anticancer Res 2001; 21(2A): 1043–1048.

    PubMed  CAS  Google Scholar 

  41. Shaughnessy JJr, Gabrea A, Qi Y, et al. Cyclin D3 at 6p21 is dysregulated by recurrent chromosomal translocations to immunoglobulin loci in multiple myeloma. Blood 2001; 98(1): 217–223.

    Article  PubMed  CAS  Google Scholar 

  42. Filipits M, Jaeger U, Pohl G, et al. Cyclin D3 is a predictive and prognostic factor in diffuse large B-cell lymphoma. Clin Cancer Res 2002; 8(3): 729–733.

    PubMed  CAS  Google Scholar 

  43. Hedberg Y, Davoodi E, Ljungberg B, Roos G, Landberg G. Cyclin E and p27 protein content in human renal cell carcinoma: clinical outcome and associations with cyclin D. Int J Cancer 2002; 102(6): 601–607.

    Article  PubMed  CAS  Google Scholar 

  44. An HX, Beckmann MW, Reifenberger G, Bender HG, Neideracher D. Gene amplification and over-expression of CDK4 in sporadic breast carcinomas is associated with high tumor cell proliferation. Am J Pathol 1999; 154(1): 113–118.

    PubMed  CAS  Google Scholar 

  45. Khatib ZA, Matsushime H, Valentine M, Shapiro DN, Sherr CJ, Look AT. Coamplification of the CDK4 gene with MDM2 and GLI in human sarcomas. Cancer Res 1993; 53(22): 5535–5541.

    PubMed  CAS  Google Scholar 

  46. Schmidt EE, Ichimura K, Reifenberger G, Collins VP. CDKN2 (pl6/MTSl) gene deletion or CDK4 amplification occurs in the majority of glioblastomas. Cancer Res 1994; 54(24): 6321–6324.

    PubMed  CAS  Google Scholar 

  47. He J, Olson JJ, James CD. Lack of pl6INK4 or retinoblastoma protein (pRb), or amplificationassociated overexpression of cdk4 is observed in distinct subsets of malignant glial tumors and cell lines. Cancer Res 1995; 55(21): 4833–4866.

    PubMed  CAS  Google Scholar 

  48. Wei G, Lonardo F, Ueda T, et al. CDK4 gene amplification in osteosarcoma: reciprocal relationship with INK4A gene alterations and mapping of 12ql3 amplicons. Int J Cancer 1999; 80(2): 199–204.

    Article  PubMed  CAS  Google Scholar 

  49. Simon R, Struckmann K, Schraml P, et al. Amplification pattern of 12ql3-ql5 genes (MDM2, CDK4, GLI) in urinary bladder cancer. Oncogene 2002; 21(16): 2476–2483.

    Article  PubMed  CAS  Google Scholar 

  50. Cairns P, Mao L, Merlo A, et al. Rates of pl6 (MTS1) mutations in primary tumors with 9p loss. Science 1994; 265(5170): 415–417.

    Article  PubMed  CAS  Google Scholar 

  51. Nobori T, Miura K, Lois A, Takabayashi K, Carson DA. Deletions of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers. Nature 1994; 368(6473): 753–756.

    Article  PubMed  CAS  Google Scholar 

  52. Spruck CH 3rd, Gonzalez-Zulueta M, Shibata A, et al. pl6 gene in uncultured tumours. Nature 1994; 370(6486): 183–184.

    Article  PubMed  Google Scholar 

  53. Herman JG, Merlo A, Mao L, et al. Inactivation of the CDKN2/pl6/MTSl gene is frequently associated with aberrant DNA methylation in all common human cancers. Cancer Res 1995; 55(20): 4525–4530.

    PubMed  CAS  Google Scholar 

  54. Borg A, Sandberg T, Nilsson K, et al. High frequency of multiple melanomas and breast and pancreas carcinomas in CDKN2A mutation-positive melanoma families. J Natl Cancer Inst 2000: 92(15): 1260–1266.

    Article  PubMed  CAS  Google Scholar 

  55. Thomas DM, Yang HS, Alexander K, Hinds PW. Role of the retinoblastoma protein in differentiation and senescence. Cancer Biol Ther 2003; 2(2): 124–130.

    PubMed  CAS  Google Scholar 

  56. Sgambato A, Cittadini A, Faraglia B, Weinstein IB. Multiple functions of p27(Kipl) and its alterations in tumor cells: a review. J Cell Physiol 2000; 183(1): 18–27.

    Article  PubMed  CAS  Google Scholar 

  57. Kawamata N, Morosetti R, Miller CW, et al. Molecular analysis of the cyclin-dependent kinase inhibitor gene p27/Kipl in human malignancies. Cancer Res 1995; 55(11): 2266–2269.

    PubMed  CAS  Google Scholar 

  58. Blain SW, Massague J. Breast cancer banishes p27 from nucleus. Nat Med 2002; 8(10): 1076–1078.

    Article  PubMed  CAS  Google Scholar 

  59. Slingerland J, Pagano M. Regulation of the cdk inhibitor p27 and its deregulation in cancer. J Cell Physiol 2000; 183(1): 10–17.

    Article  PubMed  CAS  Google Scholar 

  60. Esposito V Baldi A, De Luca A, et al. Prognostic role of the cyclin-dependent kinase inhibitor p27 in non-small cell lung cancer. Cancer Res 1997; 57(16): 3381–3385.

    PubMed  CAS  Google Scholar 

  61. Catzavelos C, Bhattacharya N, Ung YC, et al. Decreased levels of the cell-cycle inhibitor p27Kipl protein: prognostic implications in primary breast cancer. Nat Med 1997; 3(2): 227–230.

    Article  PubMed  CAS  Google Scholar 

  62. Loda M, Cukor B, Tarn SW, et al. Increased proteasome-dependent degradation of the cyclin-dependent kinase inhibitor p27 in aggressive colorectal carcinomas. Nat Med 1997; 3(2): 231–234.

    Article  PubMed  CAS  Google Scholar 

  63. Masciullo V, Sgambato A, Pacilio C, et al. Frequent loss of expression of the cyclin-dependent kinase inhibitor p27 in epithelial ovarian cancer. Cancer Res 1999; 59(15): 3790–3794.

    PubMed  CAS  Google Scholar 

  64. Singh SP, Lipman J, Goldman H, et al. Loss or altered subcellular localization of p27 in Barrett’s associated adenocarcinoma. Cancer Res 1998; 58(8): 1730–1735.

    PubMed  CAS  Google Scholar 

  65. Baldassarre G, Belletti B, Bruni P, et al. Overexpressed cyclin D3 contributes to retaining the growth inhibitor p27 in the cytoplasm of thyroid tumor cells. J Clin Invest 1999; 104(7): 865–874.

    PubMed  CAS  Google Scholar 

  66. Tsihlias J, Kapusta LR, DeBoer G, et al. Loss of cyclin-dependent kinase inhibitor p27Kipl is a novel prognostic factor in localized human prostate adenocarcinoma. Cancer Res 1998; 58(3): 542–548.

    PubMed  CAS  Google Scholar 

  67. Mizumatsu S, Tamiya T, Ono Y, et al. Expression of cell cycle regulator p27Kipl is correlated with survival of patients with astrocytoma. Clin Cancer Res 1999; 5(3): 551–557.

    PubMed  CAS  Google Scholar 

  68. Erlanson M, Portin C, Linderholm B, Lindh J, Roos G, Landberg G. Expression of cyclin E and the cyclin-dependent kinase inhibitor p27 in malignant lymphomas-prognostic implications. Blood 1998; 92(3): 770–777.

    PubMed  CAS  Google Scholar 

  69. Yamasaki L, Pagano M. Cell cycle, proteolysis and cancer. Curr Opin Cell Biol 2004; 16(6): 623–628.

    Article  PubMed  CAS  Google Scholar 

  70. Orend G, Hunter T, Ruoslahti E. Cytoplasmic displacement of cyclin E-cdk2 inhibitors p21Cipl and p27Kipl in anchorage-independent cells. Oncogene 1998; 16(20): 2575–2583.

    Article  PubMed  CAS  Google Scholar 

  71. Soucek T, Yeung RS, Hengstschlager M. Inactivation of the cyclin-dependent kinase inhibitor p27 upon loss of the tuberous sclerosis complex gene-2. Proc Natl Acad Sci USA 1998; 95(26): 15,653–15,658.

    Article  PubMed  CAS  Google Scholar 

  72. Yamasaki L. Role of the RB tumor suppressor in cancer. Cancer Treat Res 2003; 115: 209–239.

    Article  PubMed  CAS  Google Scholar 

  73. Burke L, Flieder DB, Guinee DG, et al. Prognostic implications of molecular and immunohistochemical profiles of the Rb and p53 cell cycle regulatory pathways in primary non-small cell lung carcinoma. Clin Cancer Res 2005; 11(1): 232–241.

    PubMed  CAS  Google Scholar 

  74. Zhu L, van den Heuvel S, Helin K, et al. Inhibition of cell proliferation by p107, a relative of the retinoblastoma protein. Genes Dev 1993; 7(7A): 1111–1125.

    Article  PubMed  CAS  Google Scholar 

  75. Goodrich DW, Wang NP, Qian YW, Lee EY, Lee WH. The retinoblastoma gene product regulates progression through the Gl phase of the cell cycle. Cell 1991; 67(2): 293–302.

    Article  PubMed  CAS  Google Scholar 

  76. Starostik P, Chow KN, Dean DC. Transcriptional repression and growth suppression by the pl07 pocket protein. Mol Cell Biol 1996; 16(7): 3606–3614.

    PubMed  CAS  Google Scholar 

  77. Claudio PP, Howard CM, Baldi A, et al. pl30/pRb2 has growth suppressive properties similar to yet distinctive from those of retinoblastoma family members pRb and p107. Cancer Res 1994; 54(21): 5556–5560.

    PubMed  CAS  Google Scholar 

  78. Nevins JR. Toward an understanding of the functional complexity of the E2F and retinoblastoma families. Cell Growth Differ 1998; 9(8): 585–593.

    PubMed  CAS  Google Scholar 

  79. Dyson N. The regulation of E2F by pRB-family proteins. Genes Dev 1998; 12(15): 2245–2262.

    PubMed  CAS  Google Scholar 

  80. Moberg K, Starz MA, Lees JA. E2F-4 switches from pl30 to p107 and pRB in response to cell cycle reentry. Mol Cell Biol 1996; 16(4): 1436–1449.

    PubMed  CAS  Google Scholar 

  81. Slansky JE, Farnham PJ. Introduction to the E2F family: protein structure and gene regulation. Curr Top Microbiol Immunol 1996; 208: 1–30.

    PubMed  CAS  Google Scholar 

  82. Weinberg RA. The retinoblastoma protein and cell cycle control. Cell 1995; 81(3): 323–330.

    Article  PubMed  CAS  Google Scholar 

  83. Mittnacht S. Control of pRB phosphorylation. Curr Opin Genet Dev 1998; 8(1): 21–27.

    Article  PubMed  CAS  Google Scholar 

  84. Smith EJ, Leone G, DeGregori J, Jakoi L, Nevins JR. The accumulation of an E2F-pl30 transcriptional repressor distinguishes a GO cell state from a Gl cell state. Mol Cell Biol 1996; 16(12): 6965–6976.

    PubMed  CAS  Google Scholar 

  85. Knudsen ES, Wang JYDifferential regulation of retinoblastoma protein function by specific Cdk phosphorylation sites. J Biol Chem 1996; 271(14): 8313–8320.

    Article  PubMed  CAS  Google Scholar 

  86. Lundberg AS, Weinberg RA. Functional inactivation of the retinoblastoma protein requires sequential modification by at least two distinct cyclin-cdk complexes. Mol Cell Biol 1998; 18(2): 753–761.

    PubMed  CAS  Google Scholar 

  87. Bartek J, Bartkova J, Lukas J. The retinoblastoma protein pathway in cell cycle control and cancer. Exp Cell Res 1997; 237(1): 1–6.

    Article  PubMed  CAS  Google Scholar 

  88. Sherr CJ. Cancer cell cycles. Science 1996; 274(5293): 1672–1677.

    Article  PubMed  CAS  Google Scholar 

  89. Cobrinik D, Whyte P, Peeper DS, Jacks T, Weinberg RA. Cell cycle-specific association of E2F with the pl30 ElA-binding protein. Genes Dev 1993; 7(12A): 2392–2404.

    Article  PubMed  CAS  Google Scholar 

  90. De Luca A, Baldi A, Esposito V, et al. The retinoblastoma gene family pRbJpl05, p107, pRb2/pl30 and simian virus-40 large T-antigen in human mesotheliomas. Nat Med 1997; 3(8): 913–916.

    Article  PubMed  CAS  Google Scholar 

  91. Kornblau SM, Chen N, del Giglio A, O’Brien S, Deisseroth AB. Retinoblastoma protein expression is frequently altered in chronic lymphocytic leukemia. Cancer Res 1994; 54(1): 242–246.

    PubMed  CAS  Google Scholar 

  92. Kornblau SM, Andreef M, Hu SX, et al. Low and maximally phosphorylated levels of the retinoblastoma protein confer poor prognosis in newly diagnosed acute myelogenous leukemia: a prospective study. Clin Cancer Res 1998; 4(8): 1955–1963.

    PubMed  CAS  Google Scholar 

  93. Sauerbrey A, Stammler G, Zintl F, Volm M. Expression of the retinoblastoma tumor suppressor gene (RB-1) in acute leukemia. Leuk Lymphoma 1998; 28(3–4): 275–283.

    PubMed  CAS  Google Scholar 

  94. Brambilla E, Moro D, Gazzeri S, Brambilla C. Alterations of expression of Rb, pl6(INK4A) and cyclin D1 in non-small cell lung carcinoma and their clinical significance. J Pathol 1999; 188(4): 351–360.

    Article  PubMed  CAS  Google Scholar 

  95. Baldi A, Esposito V, De Luca A, et al. Differential expression of the retinoblastoma gene family members pRb/pl05, p107, and pRb2/pl30 in lung cancer. Clin Cancer Res 1996; 2(7): 1239–1245.

    PubMed  CAS  Google Scholar 

  96. Omura K, Nagasato A, Kanehira E, et al. Retinoblastoma protein and proliferating-cell nuclear antigen expression as predictors of recurrence in well-differentiated papillary thyroid carcinoma. J Clin Oncol 1997; 15(12): 3458–3463.

    PubMed  CAS  Google Scholar 

  97. Cordon-Cardo C, Wartinger D, Petrylak D, et al. Altered expression of the retinoblastoma gene product: prognostic indicator in bladder cancer. J Natl Cancer Inst 1992; 84(16): 1251–1256.

    Article  PubMed  CAS  Google Scholar 

  98. Theodorescu D, Broder SR, Boyd JC, Mills SE, Frierson HF, Jr. p53, bcl-2 and retinoblastoma proteins as long-term prognostic markers in localized carcinoma of the prostate. J Urol 1997; 158(1): 131–137.

    Article  PubMed  CAS  Google Scholar 

  99. Tamboli P, Amin MB, Xu HJ, Linden MD. Immunohistochemical expression of retinoblastoma and p53 tumor suppressor genes in prostatic intraepithelial neoplasia: comparison with prostatic adenocarcinoma and benign prostate. Mod Pathol 1998; 11(3): 247–252.

    PubMed  CAS  Google Scholar 

  100. Dong Y, Walsh MD, McGuckin MA, et al. Reduced expression of retinoblastoma gene product (pRB) and high expression of p53 are associated with poor prognosis in ovarian cancer. Int J Cancer 1997; 74(4): 407–415.

    Article  PubMed  CAS  Google Scholar 

  101. Nakamura M, Konishi N, Tsunoda S, et al. Retinoblastoma protein expression and MIB-1 correlate with survival of patients with malignant astrocytoma. Cancer 1997; 80(2): 242–249.

    Article  PubMed  CAS  Google Scholar 

  102. Korkolopoulou PA, Angelopoulou MK, Kontopidou FN, et al. Retinoblastoma gene product and P21 (WAF1, CIP1) protein expression in non Hodgkin’s lymphomas: a multivariate survival analysis. Leuk Lymphoma 2001; 40(5–6): 647–658.

    Article  PubMed  CAS  Google Scholar 

  103. Baldi A, Esposito V, De Luca A, et al. Differential expression of Rb2/pl30 and p107 in normal human issues and in primary lung cancer. Clin Cancer Res 1997; 3(10): 1691–1697.

    PubMed  CAS  Google Scholar 

  104. Susini T, Baldi F, Howard CM, et al. Expression of the retinoblastoma-related gene Rb2/pl30 correlates with clinical outcome in endometrial cancer. J Clin Oncol 1998; 16(3): 1085–1093.

    PubMed  CAS  Google Scholar 

  105. Susini T, Massi D, Paglierani M, et al. Expression of the retinoblastoma-related gene Rb2/pl30 is downregulated in atypical endometrial hyperplasia and adenocarcinoma. Hum Pathol 2001; 32(4): 360–367.

    Article  PubMed  CAS  Google Scholar 

  106. Milde-Langosch K, Goemann C, Methner C, Rieck G, Bamberger AM, Loning T. Expression of Rb2/pl30 in breast and endometrial cancer: correlations with hormone receptor status. Br J Cancer 2001; 85(4): 546–551.

    Article  PubMed  CAS  Google Scholar 

  107. Massaro-Giordano M, Baldi G, De Luca A, Baldi A, Giordano A. Differential expression of the retinoblastoma gene family members in choroidal melanoma: prognostic significance. Clin Cancer Res 1999; 5(6): 1455–1458.

    PubMed  CAS  Google Scholar 

  108. Leoncini L, Bellan C, Cossu A, et al. Retinoblastoma-related p107 and pRb2/pl30 proteins in malignant lymphomas: distinct mechanisms of cell growth control. Clin Cancer Res 1999; 5(12): 4065–4072.

    PubMed  CAS  Google Scholar 

  109. Zamparelli A, Masciullo V, Bovicelli A, et al. Expression of cell-cycle-associated proteins pRB2/pl30 and p27kip in vulvar squamous cell carcinomas. Hum Pathol 2001; 32(1): 4–9.

    Article  PubMed  CAS  Google Scholar 

  110. Claudio PP, Zamparelli A, Garcia FU, et al. Expression of cell-cycle-regulated proteins pRb2/pl30, p107, p27(kipl), p53, mdm-2, and Ki-67 (MIB-1) in prostatic gland adenocarcinoma. Clin Cancer Res 2002; 8(6): 1808–1815.

    PubMed  CAS  Google Scholar 

  111. D’Andrilli G, Masciullo V, Bagella L, et al. Frequent loss of pRb2/pl30 in human ovarian carcinoma. Clin Cancer Res 2004; 10(9): 3098–4103.

    Article  CAS  Google Scholar 

  112. Xu B, Lim DS, Kastan MB. Two molecularly distinct G(2)/M checkpoints are induced by ionizing irradiation. Mol Cell Biol 2002; 22(4): 1049–1059.

    Article  PubMed  CAS  Google Scholar 

  113. Nyberg KA, Michelson RJ, Putnam CW, Weinert TA. Toward maintaining the genome: DNA damage and replication checkpoints. Annu Rev Genet 2002; 36: 617–656.

    Article  PubMed  CAS  Google Scholar 

  114. Donzelli M, Draetta GF. Regulating mammalian checkpoints through Cdc25 inactivation. EMBO Rep 2003; 4(7): 671–677.

    Article  PubMed  CAS  Google Scholar 

  115. Bulavin DV, Higashimoto Y, Popoff I J, et al. Initiation of a G2JM checkpoint after ultraviolet radiation requires p38 kinase. Nature 2001; 411(6833): 102–107.

    Article  PubMed  CAS  Google Scholar 

  116. Taylor WR, Stark GR. Regulation of the G2JM transition by p53. Oncogene 2001; 20(15): 1803–1815.

    Article  PubMed  CAS  Google Scholar 

  117. Zhou BB, Bartek J. Targeting the checkpoint kinases: chemosensitization versus chemoprotection. Nat Rev Cancer 2004; 4(3): 216–225.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Sbarro Institute for Cancer Research and Molecular Medicine, Temple University, Philadelphia, PA

    Giuseppina D’Andrilli MD, PhD

  2. Temple University, Philadelphia, PA and Department of Obstetrics and Gynecology, University of Bologna, Sbarro Institute for Cancer Research and Molecular Medicine, Bologna, Italy

    Alessandro Bovicelli MD, PhD

  3. Temple University, Philadelphia, PA and Departments of Human Pathology and Oncology, University of Siena, Sbarro Institute for Cancer Research and Molecular Medicine, Siena, Italy

    Antonio Giordano MD, PhD

Authors
  1. Giuseppina D’Andrilli MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Alessandro Bovicelli MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Antonio Giordano MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Sbarro Institute for Cancer Research and Molecular Medicine, Temple University, Philadelphia, PA

    Antonio Giordano MD, PhD  & Alessandro Bovicelli MD, PhD  & 

  2. Departments of Human Pathology and Oncology, University of Siena, Siena, Italy

    Antonio Giordano MD, PhD

  3. Department of Obstetrics and Gynecology, University of Bologna, Bologna, Italy

    Alessandro Bovicelli MD, PhD

  4. Departments of Gynecology-Obstetrics and Pathology, Johns Hopkins University, Baltimore, MD

    Robert J. Kurman MD, PhD

Rights and permissions

Reprints and permissions

Copyright information

© 2007 Humana Press Inc., Totowa, NJ

About this chapter

Cite this chapter

D’Andrilli, G., Bovicelli, A., Giordano, A. (2007). The Cell Cycle and the Molecular Biology of Cancer. In: Giordano, A., Bovicelli, A., Kurman, R.J. (eds) Molecular Pathology of Gynecologic Cancer. Current Clinical Oncology. Humana Press. https://doi.org/10.1007/978-1-59745-346-2_1

Download citation

  • DOI: https://doi.org/10.1007/978-1-59745-346-2_1

  • Publisher Name: Humana Press

  • Print ISBN: 978-1-58829-453-1

  • Online ISBN: 978-1-59745-346-2

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation